Clinical Trial Update: Study to Assess LX201 for Prevention of Corneal Allograft Rejection or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetrating Keratoplasty [Phase 3]

View source ↗

Summary

Phase 3 study of LX201 to prevent corneal graft rejection after penetrating keratoplasty was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Corneal Graft Rejection

Drugs mentioned

• LX201

Snippet

Sponsor: Lux Biosciences, Inc. | Conditions: Corneal Transplantation, Corneal Graft Rejection | Phase 3 | Status: TERMINATED